BZPEERReading, trust and collaboration for research
Menu

Discover

GraphFollow connections around a paper, topic or saved view.

Workspaces

HomePick up where your research flow left off.InboxHandle requests, replies and notifications from one place.CollectionsCurate reading lists, evidence sets and shareable dossiers.ResearchSee your private provenance graph, trail and imports.CollaborationMove from discovery into focused discussion rooms.PublishDraft, preview and publish full-text research articles.

Network

ExpertsFind specialists worth following or asking for help.CommunitiesJoin research circles organized around shared work.PartnersSee external organizations active around the same topics.

Opportunities

ListingsBrowse roles, calls and collaborations with clearer fit signals.

Account

Log inReturn to your reading and collaboration workspace.Create accountStart saving work, following people and joining teams.
Log inCreate account

Researcher profile

Georgia Salanti

Georgia Salanti contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate
ApplicationsMethodology

Trust snapshot

Quick read

Trust 17 - UnverifiedVerification L1Unclaimed author
4works
0followers
2topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

4 published item(s)

preprint2022arXiv

A dose-effect network meta-analysis model: an application in antidepressants

Network meta-analysis (NMA) has been used to answer a range of clinical questions about the preferable intervention for a given condition. Although the effectiveness and safety of pharmacological agents depend on the dose administered, NMA applications typically ignore the role that drugs dosage play on the results. This leads to more heterogeneity in the network. In this paper we present a suite of network meta-analysis models that incorporates the dose-effect relationship (DE-NMA) using restricted cubic splines (RCS). We extend the model into a dose-effect network meta-regression to account for study-level covariates and for groups of agents in a class-effect DE-NMA model. We apply the models to a network of aggregate data about the efficacy of 21 antidepressants and placebo for depression. We found that all antidepressants are more efficacious than placebo after a certain dose. We also identify the dose level in which each antidepressant effect exceeds that of placebo and estimate the dose beyond the effect of the antidepressants no longer increases. The DE-NMA model with RCS takes a flexible approach to modelling the dose-effect relationship in multiple interventions, so decision-makers can use them to inform treatment choice.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

A two-stage prediction model for heterogeneous effects of many treatment options: application to drugs for Multiple Sclerosis

Treatment effects vary across different patients and estimation of this variability is important for clinical decisions. The aim is to develop a model to estimate the benefit of alternative treatment options for individual patients. Hence, we developed a two-stage prediction model for heterogeneous treatment effects, by combining prognosis research and network meta-analysis methods when individual patient data is available. In a first stage, we develop a prognostic model and we predict the baseline risk of the outcome. In the second stage, we use this baseline risk score from the first stage as a single prognostic factor and effect modifier in a network meta-regression model. We apply the approach to a network meta-analysis of three randomized clinical trials comparing the relapse rate in Natalizumab, Glatiramer Acetate and Dimethyl Fumarate including 3590 patients diagnosed with relapsing-remitting multiple sclerosis. We find that the baseline risk score modifies the relative and absolute treatment effects. Several patient characteristics such as age and disability status impact on the baseline risk of relapse, and this in turn moderates the benefit that may be expected for each of the treatments. For high-risk patients, the treatment that minimizes the risk to relapse in two years is Natalizumab, whereas for low-risk patients Dimethyl Fumarate Fumarate might be a better option. Our approach can be easily extended to all outcomes of interest and has the potential to inform a personalised treatment approach.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis

Prognosis on the occurrence of relapses in individuals with Relapsing-Remitting Multiple Sclerosis (RRMS), the most common subtype of Multiple Sclerosis (MS), could support individualized decisions and disease management and could be helpful for efficiently selecting patients in future randomized clinical trials. There are only three previously published prognostic models on this, all of them with important methodological shortcomings. We aim to present the development, internal validation, and evaluation of the potential clinical benefit of a prognostic model for relapses for individuals with RRMS using real world data. We followed seven steps to develop and validate the prognostic model. Finally, we evaluated the potential clinical benefit of the developed prognostic model using decision curve analysis. We selected eight baseline prognostic factors: age, sex, prior MS treatment, months since last relapse, disease duration, number of prior relapses, expanded disability status scale (EDSS), and gadolinium enhanced lesions. We also developed a web application where the personalized probabilities to relapse within two years are calculated automatically. The optimism-corrected c-statistic is 0.65 and the optimism-corrected calibration slope was 0.92. The model appears to be clinically useful between the range 15% and 30% of the threshold probability to relapse. The prognostic model we developed offers several advantages in comparison to previously published prognostic models on RRMS. Importantly, we assessed the potential clinical benefit to better quantify the clinical impact of the model. Our web application, once externally validated in the future, could be used by patients and doctors to calculate the individualized probability to relapse within two years and to inform the management of their disease.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Rethinking the Funding Line at the Swiss National Science Foundation: Bayesian Ranking and Lottery

Funding agencies rely on peer review and expert panels to select the research deserving funding. Peer review has limitations, including bias against risky proposals or interdisciplinary research. The inter-rater reliability between reviewers and panels is low, particularly for proposals near the funding line. Funding agencies are also increasingly acknowledging the role of chance. The Swiss National Science Foundation (SNSF) introduced a lottery for proposals in the middle group of good but not excellent proposals. In this article, we introduce a Bayesian hierarchical model for the evaluation process. To rank the proposals, we estimate their expected ranks (ER), which incorporates both the magnitude and uncertainty of the estimated differences between proposals. A provisional funding line is defined based on ER and budget. The ER and its credible interval are used to identify proposals with similar quality and credible intervals that overlap with the funding line. These proposals are entered into a lottery. We illustrate the approach for two SNSF grant schemes in career and project funding. We argue that the method could reduce bias in the evaluation process. R code, data and other materials for this article are available online.

0 citations0 reviewsNo code linkedOpen access